Vadim Brusser

• Contego Medical, a medical device company, in connection with a strategic investment and distribution agreement with Medtronic.
• Kinder Morgan in its acquisition of a natural gas gathering and processing system in North Dakota from Outrigger Energy.
• Superior Ready Mix Concrete, L.P. in its acquisition by Vulcan Materials Company.
• Francisco Partners and Clearlake Capital Group, L.P. in their US$2.1 billion acquisition of Software Integrity Group from Synopsys, Inc.
• Wake Stone Corporation in its acquisition by Vulcan Materials Company.
• Nordstrom, Inc. in its acquisition by the Nordstrom family and El Puerto de Liverpool, S.A.B. de C.V. for US$6.25 billion.
• Clearlake Capital Group, L.P. in it US$4.4 billion take-private acquisition of Alteryx, Inc.
• symplr, a provider of healthcare operations software in its acquisition of IntelliCentrics.
• Victory Live in its acquisition of Logitix.
• Eagle Materials Inc. in its acquisition of aggregates business Bullskin Stone & Lime, LLC.
• Stryker in its US$4.9 billion acquisition of Inari Medical, Inc.
• Roche in its US$1.2 billion sale of its Genentech biologics manufacturing facility to Lonza.
• Roche in its US$2.7 billion acquisition of Carmot Therapeutics, Inc.
• Global retailer Coupang, Inc. in its acquisition of the business and assets of fashion retailer Farfetch Holdings plc.
• Kinder Morgan in its US$1.8 billion acquisition of NextEra Energy Partners’ South Texas assets (STX Midstream).
• Roundtable Healthcare Partners in the sale of its portfolio company, TIDI Products, to TJC, L.P.
• Represented a multinational technology corporation in the cross-border competition review of its acquisition of a leading publisher of popular PC, console, and mobile games.
• Represented a multinational medical device, pharmaceuticals, and consumer goods corporation in its acquisition of a heart pump maker.
• Represented an American pharmaceutical company in its proposed investment in and collaboration with a biopharmaceutical company developing a new class of medicines that target genetically determined dependencies that cause cancer mutations by remodeling the shape of DNA.
• Represented a healthcare company in the US$8.9 billion acquisition by its controlled subsidiary of a provider of primary, specialty and urgent care physician services.
• Represented an American global hospitality and entertainment company and its portfolio companies in various transactions, including:
  • Its acquisition of the operations of a luxury hotel from an American investment management company.
  • The proposed sale of the operations of a casino resort to another casino resort.
  • Its proposed sale of the operations of a casino resort.
• Represented an American-British-Swiss holding company in its investment in a leading healthcare provider.
• Represented a global private equity firm and its portfolio companies in various transactions, including:
  
  • The sale of a nationwide tank cleaning service to a bulk transportation service.
  • The acquisition of a space technology company to a global private equity firm.
  • The acquisition of a global security software company to a global private equity firm.
  • A sale of a leading distributor of insulation and related supplies to a leading installer and specialty distributor of insulation and building material products.
  • The sale of a British aerospace manufacturing company and its subsidiaries.
• Represented a private equity firm and its portfolio companies in connection with various matters, including:
  
  • A provider of self-service technologies and vending offerings, in its merger with a technology company.
  • A major international theater organization’s acquisition of touring Broadway show theaters.
  • A premier entertainment venue’s merger with an American global sports equipment manufacturing company.
• Represented an American private equity firm and its portfolio companies in connection with various matters, including:
  
  • A manufacturer and supplier of food and beverage preservatives, flavor and fragrance intermediates, and other additives in the antitrust aspects of the manufacturer’s sale to a developer, manufacturer, and marketer of chemical intermediates, additives, specialty chemicals, and plastics.
  • A building products distributor in the acquisition of a residential and non-residential roofing products company.
• Represented an American, Irish-domiciled pharmaceutical company as both U.S. antitrust and global coordinating counsel, securing antitrust clearance in more than a dozen jurisdictions for its sale to an American pharmaceutical company.
• Represented a Canadian multinational company in its acquisition of a stake in an asset management company.
• Represented an American-British-Swiss holding company in its acquisition of numerous American drug stores and related assets.
• Represented a hospital services provider in connection with the antitrust review of the sale of the company to another hospital services company.
• Represented a manufacturer of musculoskeletal and biotechnology products in its sale to a global medical technology company.
• Represented a designer and manufacturer of high-performance radio frequency solutions in its proposed merger of equals with a semiconductor company to form a leading provider of RF solutions and foundry services for communications, defense, and aerospace companies.
• Represented an energy infrastructure company in its acquisition of a provider of natural gas transportation and storage infrastructure.
• Represented a multinational medical device, pharmaceuticals, and consumer goods corporation in its purchase of a Swiss-American orthopedic devices maker.

Some of the above matters were handled prior to joining Sidley.